The EBMT/EHA CAR-T Cell Handbook

The EBMTEHA CAR-T Cell Handbook-1

Nicolaus Kröger • John Gribben Christian Chabannon • Ibrahim Yakoub-Agha Hermann Einsele Editors 2022 Chimeric antigen receptor T cell therapy (CAR-T) is a new class of medicinal products that are genetically engineered from T cells. It is expected that other forms of Immune Effector Cells-based therapies will soon reach the market, manufactured from other subsets […]

Continue reading →

Prevention and Treatment of Atherosclerosis: Improving State-of-the-Art Management and Search for Novel Targets

Prevention and Treatment of Atherosclerosis-2

Arnold von Eckardstein • Christoph J. Binder Editors 2022 We are proud editors of this follow-up edition of the well-received Handbook of Experimental Pharmacology Volume 170 “Atherosclerosis: Diet and Drugs,” which was published more than 15 years ago. Since then, major progress has been made in the primary and secondary prevention of atherosclerotic cardiovascular diseases […]

Continue reading →

Inequality monitoring in sexual, reproductive, maternal, newborn, child and adolescent health: a step-by-step manua

Inequality monitoring in sexua-1

World Health Organization 2022 The Constitution of the World Health Organization (WHO) states that the enjoyment of the highest attainable standard of health is a fundamental right for every human being without distinction of race, religion, political belief, or economic or social condition. Accordingly, every person should have access to the high-quality health services and […]

Continue reading →

Pandemic influenza preparedness Framework for the sharing of influenza viruses and access to vaccines and other benefits

Pandemic influenza preparedness framework for the sharing of influenza viruses and access-1

World Health Organization 2021 This second edition of the Pandemic Influenza Preparedness (PIP) Framework reflects an amendment to Annex 2, Standard Material Transfer Agreement 2, Footnote 1, as decided by the Seventy-second World Health Assembly.1 The amendment clarifies that, under certain circumstances, the indirect use of PIP Biological Materials will require the conclusion of an […]

Continue reading →

WHO guidance on the ethical conduct of controlled human infection studies

WHO guidance on the ethical conduct of controlled human infection studies-1

World Health Organization 2021 Alleviating the impact of infectious diseases on human health remains a key global health priority. In controlled human infection studies (CHIS), healthy volunteers are intentionally exposed to pathogens in a controlled environment, in order to promote understanding of the pathogenesis, transmission, prevention and treatment of infectious diseases in humans.

Continue reading →

Vaccines, Medicines and COVID-19

Vaccines, Medicines and COVID-19-1

Germán Velásquez 2022 How Can WHO Be Given a Stronger Voice? The considerable health, economic and social challenge that the world faced in early 2020 with COVID-19 continued and worsened in many parts of the world in the second half of 2020 and into 2021. Countries, international organizations, economic sectors, families and individuals have lived […]

Continue reading →